Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial
ObjectiveTo observe the effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome(PCOS).MethodsA total of 64 overweight/obese women with PCOS diagnosed via the Rotterdam criteria were randomly assigned...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-06-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2023.1156521/full |
| _version_ | 1797810269074751488 |
|---|---|
| author | Qing Wen Song Fang Yanjing Liang Yuting Tian Yiding Chen Jun Yuan Qiu Chen |
| author_facet | Qing Wen Song Fang Yanjing Liang Yuting Tian Yiding Chen Jun Yuan Qiu Chen |
| author_sort | Qing Wen |
| collection | DOAJ |
| description | ObjectiveTo observe the effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome(PCOS).MethodsA total of 64 overweight/obese women with PCOS diagnosed via the Rotterdam criteria were randomly assigned to metformin(MET) 850 mg twice a day(BID) or combined MET 850 mg BID with beinaglutide (COMB) starting at 0.1mg three times a day(TID)and increasing to 0.2mg TID two weeks later. The main endpoints were changes in anthropometric measurements of obesity. Glucose and lipid metabolic, gonadal profiles, and antral follicle count changes as secondary outcomes were also observed.Results60(93.75%) patients completed the study. In terms of lowering weight, body mass index (BMI),waist circumference(WC) and waist to height ratio(WHtR), COMB treatment outperformed MET monotherapy. Subjects in the COMB arm lost weight 4.54±3.16kg compared with a 2.47±3.59kg loss in the MET arm. In the COMB group, BMI,WC and WHtR were reduced significantly compared with that in the MET group, respectively. COMB therapy is also more favorable in the reduction of fasting insulin(FINS), total testosterone(TT), and homeostasis model assessment–insulin resistance(HOMA-IR) when compared to MET therapy. Antral follicle count and ovarian volume were non-significantly changed in both groups.The most frequent side effects in both groups were mild and moderate digestive symptoms. Itching and induration at the injection site were reported with COMB treatment.ConclusionShort-term combined treatment with beinaglutide and metformin appears superior to metformin monotherapy in lowering body weight, BMI, WC,WHtR and improving insulin sensitivity and androgen excess in women with PCOS and obesity, with tolerable adverse events.Clinical trial registrationhttps://www.chictr.org.cn/listbycreater.aspx, identifier ChiCTR2000033741. |
| first_indexed | 2024-03-13T07:05:35Z |
| format | Article |
| id | doaj.art-890d601e19b14b1aa081941db5f05c98 |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-03-13T07:05:35Z |
| publishDate | 2023-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-890d601e19b14b1aa081941db5f05c982023-06-06T11:49:00ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922023-06-011410.3389/fendo.2023.11565211156521Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trialQing Wen0Song Fang1Yanjing Liang2Yuting Tian3Yiding Chen4Jun Yuan5Qiu Chen6Medical Department of Endocrinology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, ChinaMedical Department of Endocrinology, The Traditional Chinese Medicine Hospital of Longquanyi, Chengdu, ChinaMedical Department of Endocrinology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, ChinaMedical Department of Endocrinology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, ChinaMedical Department of Endocrinology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, ChinaMedical Department of Endocrinology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, ChinaMedical Department of Endocrinology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, ChinaObjectiveTo observe the effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome(PCOS).MethodsA total of 64 overweight/obese women with PCOS diagnosed via the Rotterdam criteria were randomly assigned to metformin(MET) 850 mg twice a day(BID) or combined MET 850 mg BID with beinaglutide (COMB) starting at 0.1mg three times a day(TID)and increasing to 0.2mg TID two weeks later. The main endpoints were changes in anthropometric measurements of obesity. Glucose and lipid metabolic, gonadal profiles, and antral follicle count changes as secondary outcomes were also observed.Results60(93.75%) patients completed the study. In terms of lowering weight, body mass index (BMI),waist circumference(WC) and waist to height ratio(WHtR), COMB treatment outperformed MET monotherapy. Subjects in the COMB arm lost weight 4.54±3.16kg compared with a 2.47±3.59kg loss in the MET arm. In the COMB group, BMI,WC and WHtR were reduced significantly compared with that in the MET group, respectively. COMB therapy is also more favorable in the reduction of fasting insulin(FINS), total testosterone(TT), and homeostasis model assessment–insulin resistance(HOMA-IR) when compared to MET therapy. Antral follicle count and ovarian volume were non-significantly changed in both groups.The most frequent side effects in both groups were mild and moderate digestive symptoms. Itching and induration at the injection site were reported with COMB treatment.ConclusionShort-term combined treatment with beinaglutide and metformin appears superior to metformin monotherapy in lowering body weight, BMI, WC,WHtR and improving insulin sensitivity and androgen excess in women with PCOS and obesity, with tolerable adverse events.Clinical trial registrationhttps://www.chictr.org.cn/listbycreater.aspx, identifier ChiCTR2000033741.https://www.frontiersin.org/articles/10.3389/fendo.2023.1156521/fullbeinaglutidemetforminpolycystic ovary syndromeobesityweight lossgonadal profiles |
| spellingShingle | Qing Wen Song Fang Yanjing Liang Yuting Tian Yiding Chen Jun Yuan Qiu Chen Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial Frontiers in Endocrinology beinaglutide metformin polycystic ovary syndrome obesity weight loss gonadal profiles |
| title | Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial |
| title_full | Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial |
| title_fullStr | Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial |
| title_full_unstemmed | Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial |
| title_short | Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial |
| title_sort | short term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome a pilot randomized trial |
| topic | beinaglutide metformin polycystic ovary syndrome obesity weight loss gonadal profiles |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2023.1156521/full |
| work_keys_str_mv | AT qingwen shorttermeffectofbeinaglutidecombinedwithmetforminversusmetforminaloneonweightlossandmetabolicprofilesinobesepatientswithpolycysticovarysyndromeapilotrandomizedtrial AT songfang shorttermeffectofbeinaglutidecombinedwithmetforminversusmetforminaloneonweightlossandmetabolicprofilesinobesepatientswithpolycysticovarysyndromeapilotrandomizedtrial AT yanjingliang shorttermeffectofbeinaglutidecombinedwithmetforminversusmetforminaloneonweightlossandmetabolicprofilesinobesepatientswithpolycysticovarysyndromeapilotrandomizedtrial AT yutingtian shorttermeffectofbeinaglutidecombinedwithmetforminversusmetforminaloneonweightlossandmetabolicprofilesinobesepatientswithpolycysticovarysyndromeapilotrandomizedtrial AT yidingchen shorttermeffectofbeinaglutidecombinedwithmetforminversusmetforminaloneonweightlossandmetabolicprofilesinobesepatientswithpolycysticovarysyndromeapilotrandomizedtrial AT junyuan shorttermeffectofbeinaglutidecombinedwithmetforminversusmetforminaloneonweightlossandmetabolicprofilesinobesepatientswithpolycysticovarysyndromeapilotrandomizedtrial AT qiuchen shorttermeffectofbeinaglutidecombinedwithmetforminversusmetforminaloneonweightlossandmetabolicprofilesinobesepatientswithpolycysticovarysyndromeapilotrandomizedtrial |